A major breakthrough in the cordyceps world, or in the near future people will be able to cultivate their own cordyceps
Release Time:2018-11-28 Content Source:中国虫草交易网

The most important aspect of the increase in the price of Cordyceps sinensis is that because of the scarcity of Cordyceps sinensis resources, people have been trying to cultivate Cordyceps sinensis, but the situation of Cordyceps sinensis to achieve artificial breeding is faced with two major difficulties. The first is how to raise insects and multiply them. The second is to allow Cordyceps sinensis to grow both worms and "grass" after infection.

In 2017, the company founded by Yangdarong, a retired researcher at the Xishuangbanna Tropical Botanical Garden of the Chinese Academy of Sciences, cultivated more than 10,000 cordyceps sinensis indoors in Shangri-La City, and more than 60 square meters of Alpine Meadows at an altitude of 4,500 meters in Xiaozhongdian. The demonstration base semi-artificially cultivated 6 cordyceps. This year, the demonstration base was expanded to 20 acres. It is expected that in 2019, it will produce 30 kilograms to 50 kilograms of cordyceps in the Shangri-La City base shed and snow-capped mountain field base.

Yangdarong has been solving the problem of "how to raise insects" for the first 20 years. The special high altitude ecological adaptation of bat moth is the biggest obstacle to artificial reproduction. At high altitudes of cold, high ultraviolet light, and thin air, a larva generally needs to peel at least 6 times. At high altitudes, it takes 8 to 9 times to enter the pre-pupa and pupa period. It takes about 3 years to complete a generation. The area with high altitude can only complete one generation in almost 5 years. How to simulate their living environment, adapt them to the experimental environment at low altitude, and achieve large-scale reproduction is a key issue that scientists have conquered.

In 1995, Yangdarong's team fed the first pair of bat moths that could be mated indoors, laying 586 eggs and officially starting indoor rearing. Three years later, more than 40,000 larvae were bred. "At first there were many diseases and they did not become scale. "Yangdarong said that by 2002, more than 200,000 larvae were successfully fed; In 2005, it reached the size of 500,000 to 600,000 larvae.

So far, some institutions and companies have mastered the technology of combining Cordyceps sinensis with bat moth larvae, but the "secret" of indoor large-scale breeding of bat moth larvae is rarely known. Every year, Yangdarong's company supplies bat moth larvae to more than 20 scientific research units, colleges and universities, and companies across the country for research.

This year, Yangdarong built a demonstration base in Shangri-La. The purpose of the demonstration base is to cooperate with local herdsmen to promote the semi-artificial cultivation of Cordyceps sinensis. The main method is to release artificially bred bat moth larvae and artificially cultivated fungus into the natural environment, increase the source of host insects and bacteria, and still rely on their natural growth and infection.

The current research and demonstration results can basically achieve a yield of 1 kilogram per Mu, about 1,800 Cordyceps sinensis, calculated according to the average market price of 30 yuan/root to 50 yuan/root, and 1 Mu of land can bring 50,000 yuan to 80,000 yuan for herdsmen. Income.

Cordyceps sinensis, which is usually used to treat back pain, jaundice, and deficiency, is also used to treat tuberculosis, asthma, bronchitis, emphysema and so on.

In the past, Cordyceps sinensis was considered to contain a large number of pyrethroids with anti-cancer and antibacterial activities. This year, researchers at the Shanghai Institute of Plant Physiology and Ecology at the Chinese Academy of Sciences recently confirmed that there is no pyrethroid synthesis gene in Cordyceps sinensis. However, the efficacy of Pharmacopoeia records, as well as the use of it to enhance immunity, especially to speed up postoperative recovery, is still clinically positive. However, the specific components of Cordyceps sinensis correspond to various effects and have not yet found a definitive answer in medicine.

On March 8, this year, the website of the State Food and Drug Administration issued a notice on the suspension of the use of Cordyceps sinensis for health food pilot work. Why stop the trial work of Cordyceps sinensis for health food? The State Administration of Food and Drug Administration stated that Cordyceps sinensis is a Chinese herbal medicine that is not a dual-use drug and can not be used as a raw material for health products.